Hypofractionated chemoradiotherapy with tislelizumab and surufatinib for unresectable stage III NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study is a randomized phase II trial enrolling adults with unresectable stage III NSCLC. Participants receive hypofractionated radiotherapy with chemotherapy and either (A) concurrent tislelizumab and surufatinib followed by consolidation with tislelizumab plus surufatinib, or (B) concurrent tislelizumab with radiotherapy followed by consolidation with tislelizumab. The trial aims to compare efficacy and safety between the two regimens. Eligible patients have good performance status, adequate organ function, and no known driver mutations. Primary outcomes likely include tumor response and safety, with secondary endpoints such as progression-free survival and overall survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males or females aged 18 to 75 years or older;
* Patients must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC);
* Unresectable Stage III disease according to AJCC 8th staging system;
* Negative for known driver gene mutations；
* Newly diagnosed patients or patients treated with ≤ 4 cycles of chemotherapy combined with or without immunotherapy;
* Expected survival ≥ 12 weeks;
* WHO Performance Status (PS) score of 0 or 1;
* Female subjects must not be breastfeeding;
* Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days \[one ovulation cycle\] plus approximately five half-lives of the study drug);
* Adequate organ and bone marrow function as defined by the following criteria:
* Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL;
* Absolute neutrophil count ≥ 1.5 × 10⁹/L;
* Platelets ≥ 100 × 10⁹/L;
* Hemoglobin ≥ 9.0 g/dL;
* Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);
* Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);
* AST and ALT ≤ 2.5 × ULN.

Exclusion Criteria:

* Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
* Mixed small cell and non-small cell lung cancer histology;
* Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;
* Active or prior documented autoimmune disease within the past 2 years;
* Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);
* History of primary immunodeficiency;
* History of organ transplant that requires therapeutic immunosuppression;
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;
* Known history of tuberculosis;
* History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
* Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.

Where it's running

• Sun yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: DaQuan Wang, MD
• Email: wangdq@sysucc.org.cn
• Phone: +862087343031

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Microwave ablation plus tislelizumab and docetaxel for advanced NSCLC after first-line immunotherapy progression

  This treatment tests whether adding microwave ablation to tislelizumab and docetaxel can help people with advanced non‑small cell lung cancer whose disease progressed after first‑line immunotherapy plus chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07528274

• Concurrent chemoradiotherapy with surufatinib and tislelizumab for unresectable stage III non-small cell lung cancer

  This tests whether adding surufatinib and tislelizumab to standard concurrent chemoradiotherapy, followed by continuing both drugs as consolidation, helps people with unresectable stage III non-small cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07086456

• Cryoablation with Tislelizumab and Chemotherapy for Non-small Cell Lung Cancer

  This study is testing if combining a freezing treatment with a new drug and chemotherapy can help people with early-stage lung cancer before surgery and improve their chances of survival.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06939127

• Investigating KQB365 for treating advanced solid tumors

  This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 11 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 10 other locations · NCT06720987

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.